Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

419P - XELOX/XELIRI alternative regimen as first-line treatment of metastatic colorectal cancer (CCRCTO-2: TROT): A phase II study


16 Sep 2021


ePoster Display


Clinical Research

Tumour Site

Colon and Rectal Cancer




Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698


Y. HAN1, R. Zhang2, Y. Liu1, P. Han1, H. Yuan1, X. Wei1, H. Chen1, L. Bai1, Y. Zhang1, J. Zhu3

Author affiliations

  • 1 Oncology, Harbin Medical University Cancer Hospital, 150040 - Harbin/CN
  • 2 Oncology, Liaoning Cancer Hospital and Institute, 110042 - shenyang/CN
  • 3 Oncology, Fudan University Shanghai cancer center, 200433 - shanghai/CN

Abstract 419P


Since 2000, the combination of three drugs and targeted drugs has further improved the survival of metastatic colorectal carcinoma(mCRC), while the incidence of side effects of triple regimens over grade 3 are much higher than double regimens. Since adjusting the dosage of drugs can’t avoid serious toxicity, here we present a new methode of optimizing the scheme by adjusting the time and mode of administration.


TROT is a prospective, open-label, multicentric phase II randomized trial in which unresectable and previously untreated mCRC patients are randomized to receive first-line XELOX followed by XELIRI after disease progression ± bevacizumab(arm A) or these two schemes alternatively use ± bevacizumab of every 2 cycles until disease progression(arm B). The primary endpoint is to compare the efficacy of these two treatment strategies in terms of time to failure of strategy (TFS) and secondary objectives were ORR、DCR、OS and safety. The curative effect will evaluate in every 2 cycles.


66 patients were enrolled.6 patients were lost to follow or fall off. The analysis of curative effect has been evaluated in 31 patients in the arm A and 29 patients in the arm B.ORR was 27.6% in the first-line and 11.5% in the second-line in the arm A vs 67.7% in the arm B (P < 0.001).The DCR was 89.7% in the first-line and 57.7% in the second-line in the arm A vs 100% in the in the arm B (P < 0.001). ETS was 64.5% and DpR was 46% in the arm B. Median TFS was 12.9 months in arm A vs 12.0 months in arm B (P =0.735,HR 1.103). Median OS was 20.4 months in arm A vs 18.8 months in arm B (P=0.712,HR 0.887).Grade ≥3 AEs occurred in 10 patients (32%)in arm B vs 21 patients (72.4%)in arm A(P<0.001). No treatment-related death was reported. There were significantly lower AEs than current triplet regimens.


XELOX/XELIRI alternate regimen ± bevacizumab,compared with first-line XELOX followed by XELIRI after disease progression ± bevacizumab,can improve the effect of tumour shrinkage and significantly reduce treatment-related side effects in mCRC patients with widespread metastasis,and this alternate regimen may become an alternative for patients who can’t tolerate the three-drug combination regimen.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Yu Han.


Has not received any funding.


All authors have declared no conflicts of interest.

Clinical trial information


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.